title: Alternating radiotherapy and chemotherapy schedules in limited small cell lung cancer: analysis of local chest recurrences.
abstract: An analysis of the chest recurrences was conducted in 72 consecutive patients with limited small cell lung cancer treated in two successive phase II trials alternating six induction chemotherapy courses and three series of thoracic radiotherapy, followed by maintenance chemotherapy. The total radiation dose was 45 Gy (3 series of 15 Gy) in the first trial, and 55 (20, 20 and 15 Gy) in the second. The effect of the irradiated volume was investigated by comparing the local relapse rates in the group of patients treated by radiation fields encompassing the initial tumor volume to another group in which the initial target volume was not fully covered by radiation fields. The definition of these two groups was performed retrospectively by examination of radiological, fiberoptic bronchoscopy initial findings, technical radiation charts and check films. The local recurrence rate were 33 and 36% in each group (no significant difference). This finding could suggest that tumor shrinkage after chemotherapy might allow the use of "reduced" radiation volumes. However, the limited number of patients does not permit a definite conclusion. The effect of radiation dose was investigated by comparing the local control rates in the two consecutive trials which delivered 45 and 55 Gy, respectively. No difference in long-term local control was found: the addition of 10 Gy in the second trial only seemed to delay the appearance of local recurrences by 6 months. Twenty percent of patients died from a local relapse without evidence of distant metastases.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Institut Gustave-Roussy, Villejuif, France.
authors.forename: R
authors.initials: R
authors.lastname: Arriagada
authors.forename: B
authors.initials: B
authors.lastname: Pellae-Cosset
authors.forename: J C
authors.initials: JC
authors.lastname: Ladron de Guevara
authors.forename: H
authors.initials: H
authors.lastname: el Bakry
authors.forename: F
authors.initials: F
authors.lastname: Benna
authors.forename: M
authors.initials: M
authors.lastname: Martin
authors.forename: H
authors.initials: H
authors.lastname: de Cremoux
authors.forename: P
authors.initials: P
authors.lastname: Baldeyrou
authors.forename: M L
authors.initials: ML
authors.lastname: Cerrina
authors.forename: T
authors.initials: T
authors.lastname: Le Chevalier
mesh_terms: D000206:Actuarial Analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D011879:Radiotherapy Dosage
chemical_list: D000970:Antineoplastic Agents